Birdwatch Note
2023-08-25 21:42:46 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
EBC-46 has shown efficacy to reduce cancer in animal studies only. Clinical trials have since commenced for skin, head and neck, and soft tissue cancers in humans. In 2020 the FDA approved an EBC-46–based medication Stelfonta, to treat mast cell cancer in dogs. https://news.stanford.edu/2022/10/03/breakthrough-production-acclaimed-cancer-treating-drug/
Written by F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1695181665578942924
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1695190002055970932
- noteId - 1695190002055970932
- participantId -
- noteAuthorParticipantId - F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D Participant Details
- createdAtMillis - 1692999766254
- tweetId - 1695181665578942924
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- EBC-46 has shown efficacy to reduce cancer in animal studies only. Clinical trials have since commenced for skin, head and neck, and soft tissue cancers in humans. In 2020 the FDA approved an EBC-46–based medication Stelfonta, to treat mast cell cancer in dogs. https://news.stanford.edu/2022/10/03/breakthrough-production-acclaimed-cancer-treating-drug/
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-08-25 21:42:46 UTC (1692999766254) |
2023-08-26 00:13:01 UTC (1693008781653) |
CURRENTLY_RATED_HELPFUL | 2023-08-26 02:11:58 UTC (1693015918586) |
CURRENTLY_RATED_HELPFUL | 2023-08-26 00:13:01 UTC (1693008781653) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
rated at | rated by | |
2023-08-25 19:16:04 -0500 | Rating Details | |
2023-08-25 17:23:05 -0500 | Rating Details | |
2023-08-25 17:21:01 -0500 | Rating Details | |
2023-08-25 17:20:43 -0500 | Rating Details | |
2023-08-25 17:20:41 -0500 | Rating Details | |
2023-08-25 17:19:19 -0500 | Rating Details | |
2023-08-25 17:19:06 -0500 | Rating Details | |
2023-08-25 17:18:06 -0500 | Rating Details | |
2023-08-25 17:17:15 -0500 | Rating Details | |
2023-08-25 17:16:53 -0500 | Rating Details | |
2023-08-25 17:16:52 -0500 | Rating Details | |
2023-08-25 17:15:47 -0500 | Rating Details | |
2023-08-25 17:14:21 -0500 | Rating Details | |
2023-08-25 17:13:05 -0500 | Rating Details | |
2023-08-25 17:12:54 -0500 | Rating Details | |
2023-08-25 17:12:47 -0500 | Rating Details | |
2023-08-25 17:09:45 -0500 | Rating Details | |
2023-08-25 17:07:58 -0500 | Rating Details | |
2023-08-25 17:07:53 -0500 | Rating Details | |
2023-08-25 17:07:40 -0500 | Rating Details | |
2023-08-25 17:07:32 -0500 | Rating Details | |
2023-08-25 17:07:25 -0500 | Rating Details | |
2023-08-25 17:06:28 -0500 | Rating Details | |
2023-08-25 17:05:20 -0500 | Rating Details | |
2023-08-25 17:05:04 -0500 | Rating Details | |
2023-08-25 17:04:20 -0500 | Rating Details | |
2023-08-25 17:03:39 -0500 | Rating Details | |
2023-08-25 17:02:53 -0500 | Rating Details | |
2023-08-25 17:01:52 -0500 | Rating Details | |
2023-08-25 17:01:15 -0500 | Rating Details | |
2023-08-25 17:00:53 -0500 | Rating Details | |
2023-08-25 17:00:50 -0500 | Rating Details | |
2023-08-25 17:00:40 -0500 | Rating Details | |
2023-08-25 17:00:01 -0500 | Rating Details | |
2023-08-25 16:59:44 -0500 | Rating Details | |
2023-08-25 16:58:56 -0500 | Rating Details | |
2023-08-25 16:58:41 -0500 | Rating Details | |
2023-08-25 16:58:14 -0500 | Rating Details | |
2023-08-25 16:57:32 -0500 | Rating Details | |
2023-08-25 16:57:02 -0500 | Rating Details | |
2023-08-25 16:56:28 -0500 | Rating Details | |
2023-08-25 16:56:27 -0500 | Rating Details | |
2023-08-25 16:55:38 -0500 | Rating Details | |
2023-08-25 16:55:18 -0500 | Rating Details | |
2023-08-25 16:55:18 -0500 | Rating Details | |
2023-08-25 16:54:55 -0500 | Rating Details | |
2023-08-25 16:54:29 -0500 | Rating Details | |
2023-08-25 16:54:10 -0500 | Rating Details | |
2023-08-25 16:52:58 -0500 | Rating Details | |
2023-08-25 16:52:04 -0500 | Rating Details | |
2023-08-25 16:50:38 -0500 | Rating Details | |
2023-08-25 16:50:36 -0500 | Rating Details | |
2023-08-25 16:50:29 -0500 | Rating Details | |
2023-08-25 16:49:00 -0500 | Rating Details | |
2023-08-26 18:48:42 -0500 | Rating Details | |
2023-08-26 18:30:17 -0500 | Rating Details | |
2023-08-26 18:22:09 -0500 | Rating Details | |
2023-08-26 17:49:53 -0500 | Rating Details | |
2023-08-26 16:31:41 -0500 | Rating Details | |
2023-08-26 16:09:02 -0500 | Rating Details | |
2023-08-26 16:08:18 -0500 | Rating Details | |
2023-08-26 15:56:53 -0500 | Rating Details | |
2023-08-26 15:49:45 -0500 | Rating Details | |
2023-08-26 15:46:28 -0500 | Rating Details | |
2023-08-26 13:56:32 -0500 | Rating Details | |
2023-08-26 13:49:05 -0500 | Rating Details | |
2023-08-26 13:34:07 -0500 | Rating Details | |
2023-08-26 13:33:03 -0500 | Rating Details | |
2023-08-26 13:31:17 -0500 | Rating Details | |
2023-08-26 12:48:52 -0500 | Rating Details | |
2023-08-26 12:48:51 -0500 | Rating Details | |
2023-08-26 12:20:56 -0500 | Rating Details | |
2023-08-26 12:11:45 -0500 | Rating Details | |
2023-08-26 10:37:51 -0500 | Rating Details | |
2023-08-26 09:39:42 -0500 | Rating Details | |
2023-08-26 09:09:17 -0500 | Rating Details | |
2023-08-26 08:14:25 -0500 | Rating Details | |
2023-08-26 08:12:23 -0500 | Rating Details | |
2023-08-26 07:51:50 -0500 | Rating Details | |
2023-08-26 07:46:44 -0500 | Rating Details | |
2023-08-26 07:32:54 -0500 | Rating Details | |
2023-08-26 07:26:47 -0500 | Rating Details | |
2023-08-26 07:26:34 -0500 | Rating Details | |
2023-08-26 06:56:10 -0500 | Rating Details | |
2023-08-26 06:02:09 -0500 | Rating Details | |
2023-08-26 05:48:20 -0500 | Rating Details | |
2023-08-26 05:18:14 -0500 | Rating Details | |
2023-08-26 05:04:45 -0500 | Rating Details | |
2023-08-26 05:03:01 -0500 | Rating Details | |
2023-08-26 05:02:05 -0500 | Rating Details | |
2023-08-26 04:28:27 -0500 | Rating Details | |
2023-08-26 04:26:52 -0500 | Rating Details | |
2023-08-26 04:05:20 -0500 | Rating Details | |
2023-08-26 03:50:10 -0500 | Rating Details | |
2023-08-26 03:39:41 -0500 | Rating Details | |
2023-08-26 03:20:33 -0500 | Rating Details | |
2023-08-26 03:03:13 -0500 | Rating Details | |
2023-08-26 01:45:09 -0500 | Rating Details | |
2023-08-26 01:00:14 -0500 | Rating Details | |
2023-08-26 00:59:48 -0500 | Rating Details | |
2023-08-25 23:47:21 -0500 | Rating Details | |
2023-08-25 23:15:00 -0500 | Rating Details | |
2023-08-25 22:51:45 -0500 | Rating Details | |
2023-08-25 20:01:22 -0500 | Rating Details | |
2023-08-25 19:48:57 -0500 | Rating Details | |
2023-08-27 15:42:01 -0500 | Rating Details | |
2023-08-27 08:45:58 -0500 | Rating Details | |
2023-08-27 05:04:37 -0500 | Rating Details | |
2023-08-27 03:09:40 -0500 | Rating Details | |
2023-08-27 00:27:34 -0500 | Rating Details | |
2023-08-26 20:40:56 -0500 | Rating Details | |
2023-08-28 22:06:59 -0500 | Rating Details | |
2023-08-26 14:39:01 -0500 | Rating Details | |
2023-08-26 07:30:14 -0500 | Rating Details |